# Targeted Alpha Therapy Using Astatine (At-211) Against Differentiated Thyroid Cancer

> **NCT05275946** · PHASE1 · COMPLETED · sponsor: **Osaka University** · enrollment: 11 (actual)

## Conditions studied

- Thyroid Cancer

## Interventions

- **DRUG:** Targeted alpha therapy

## Key facts

- **NCT ID:** NCT05275946
- **Lead sponsor:** Osaka University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-20
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-03-31
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2025-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05275946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05275946, "Targeted Alpha Therapy Using Astatine (At-211) Against Differentiated Thyroid Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05275946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*